We can’t show the full text here under this license. Use the link below to read it at the source.
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?
Temozolomide chemotherapy for new glioblastoma patients: Does the timing of treatment affect outcomes?
AI simplified
Abstract
In a cohort of 810 glioblastoma patients, 39% received temozolomide in the morning.
- No significant difference in was observed between patients taking temozolomide in the morning and those taking it in the evening.
- In the CENTRIC trial, the median overall survival was 20.6 months for morning administration and 21.1 months for evening administration.
- In the CORE trial, the median overall survival was 10.9 months for morning administration and 11.4 months for evening administration.
- Morning administration of temozolomide was associated with a higher incidence of compared to evening administration.
- Bone marrow toxicity rates were 33% for morning versus 11% for evening in CENTRIC, and 24% for morning versus 3% for evening in CORE.
AI simplified
Key numbers
20.6 months
Median in CENTRIC
Adjusted median for morning vs. evening administration.
33%
Higher Rate
Proportion of patients with in CENTRIC.
5.3 months
Longer in CORE
Adjusted median for morning vs. evening administration in CORE.